Free Trial
NYSEAMERICAN:CCEL

Cryo-Cell International (CCEL) Stock Price, News & Analysis

Cryo-Cell International logo
$7.71 -0.34 (-4.22%)
Closing price 02/21/2025 04:10 PM Eastern
Extended Trading
$7.83 +0.12 (+1.56%)
As of 02/21/2025 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cryo-Cell International Stock (NYSEAMERICAN:CCEL)

Key Stats

Today's Range
$7.66
$8.19
50-Day Range
N/A
52-Week Range
$4.47
$9.50
Volume
15,368 shs
Average Volume
14,819 shs
Market Capitalization
$62.14 million
P/E Ratio
N/A
Dividend Yield
12.97%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Cryo-Cell International Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

CCEL MarketRank™: 

Cryo-Cell International scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cryo-Cell International.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cryo-Cell International is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cryo-Cell International is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.41% of the float of Cryo-Cell International has been sold short.
  • Short Interest Ratio / Days to Cover

    Cryo-Cell International has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cryo-Cell International has recently increased by 3.18%, indicating that investor sentiment is decreasing.
  • Dividend Leadership

    Cryo-Cell International is a leading dividend payer. It pays a dividend yield of 12.42%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Cryo-Cell International does not have a long track record of dividend growth.

  • Read more about Cryo-Cell International's dividend.
  • Percentage of Shares Shorted

    0.41% of the float of Cryo-Cell International has been sold short.
  • Short Interest Ratio / Days to Cover

    Cryo-Cell International has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cryo-Cell International has recently increased by 3.18%, indicating that investor sentiment is decreasing.
  • Search Interest

    2 people have searched for CCEL on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cryo-Cell International insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    36.86% of the stock of Cryo-Cell International is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 10.44% of the stock of Cryo-Cell International is held by institutions.

  • Read more about Cryo-Cell International's insider trading history.
Receive CCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter.

CCEL Stock News Headlines

CRYO-CELL International, Inc. trading resumes
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
CRYO-CELL International, Inc. trading halted, volatility trading pause
Cryo-Cell International Inc CCEL
See More Headlines

CCEL Stock Analysis - Frequently Asked Questions

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) posted its earnings results on Tuesday, October, 15th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.11. The business earned $8.07 million during the quarter. Cryo-Cell International had a negative trailing twelve-month return on equity of 42.06% and a negative net margin of 28.03%.

Cryo-Cell International's top institutional shareholders include Topline Capital Management LLC (0.59%), Northern Trust Corp (0.48%), Heron Bay Capital Management (0.39%) and CreativeOne Wealth LLC (0.19%).
View institutional ownership trends
.

Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cryo-Cell International investors own include Meta Platforms (META), Alimera Sciences (ALIM), Catalyst Biosciences (CBIO), iClick Interactive Asia Group (ICLK), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX) and Aspen Group (ASPU).

Company Calendar

Last Earnings
10/15/2024
Ex-Dividend for 11/29 Dividend
11/15/2024
Dividend Payable
11/29/2024
Ex-Dividend for 2/28 Dividend
2/14/2025
Today
2/22/2025
Dividend Payable
2/28/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
Healthcare
Current Symbol
NYSEAMERICAN:CCEL
Employees
90
Year Founded
N/A

Profitability

Net Income
$-9,520,000.00
Pretax Margin
-38.78%

Debt

Sales & Book Value

Annual Sales
$31.34 million
Cash Flow
$0.68 per share
Book Value
($1.33) per share

Miscellaneous

Free Float
5,090,000
Market Cap
$62.14 million
Optionable
Not Optionable
Beta
0.53

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NYSEAMERICAN:CCEL) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners